Johnson & Johnson Net Long-Term Debt 2010-2025 | JNJ
Johnson & Johnson annual/quarterly net long-term debt history and growth rate from 2010 to 2025. Net long-term debt can be defined as the net amount of long term debt issued and repaid. This field is either calculated as the sum of the long term debt fields or used if a company does not report debt issued and repaid separately
- Johnson & Johnson net long-term debt for the quarter ending March 31, 2025 was $8.387B, a 838600% increase year-over-year.
- Johnson & Johnson net long-term debt for the twelve months ending March 31, 2025 was $25.306B, a 394.16% increase year-over-year.
- Johnson & Johnson annual net long-term debt for 2024 was $5.207B, a 435.72% decline from 2023.
- Johnson & Johnson annual net long-term debt for 2023 was $-1.551B, a 27.25% decline from 2022.
- Johnson & Johnson annual net long-term debt for 2022 was $-2.132B, a 18.64% increase from 2021.
Johnson & Johnson Annual Net Long-Term Debt
(Millions of US $) |
| 2024 |
$5,207 |
| 2023 |
$-1,551 |
| 2022 |
$-2,132 |
| 2021 |
$-1,797 |
| 2020 |
$6,367 |
| 2019 |
$-2,820 |
| 2018 |
$-1,550 |
| 2017 |
$7,215 |
| 2016 |
$9,781 |
| 2015 |
$7 |
| 2014 |
$254 |
| 2013 |
$2,014 |
| 2012 |
$-759 |
| 2011 |
$4,454 |
| 2010 |
$1,086 |
| 2009 |
$-210 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$368.659B |
$88.821B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
